Panacea Global, Inc. (PGI) is a biotechnology company focusing on developing and commercializing products for the early detection, diagnosis and monitoring the recurrence of cancer. Panacea’s novel product is a blood test that can detect the presence of cancer in humans using a novel cancer biomarker named Human Aspartyl (Asparaginyl) B-Hydroxylase (HAAH), an enzyme which is over expressed in cancer cells and is the foundation of our breakthrough technology.

Cancer Diagnostics PGI offers patients with accurate, reliable and fast cancer detection PGI offers patients with non-invasive, highly accurate, reliable, fast and cost-effective cancer detection tests, which can be used for early diagnosis, remission and recurrence of cancer following treatment.